€551.80
0.33% today
Brüssel, Nov 21, 01:15 pm CET
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

arGEN-X Stock price

€553.60
+41.40 8.08% 1M
+219.00 65.45% 6M
+210.10 61.16% YTD
+102.90 22.83% 1Y
+310.20 127.44% 3Y
+420.40 315.62% 5Y
+547.00 8,287.88% 10Y
Brüssel, Closing price Wed, Nov 20 2024
+21.40 4.02%
ISIN
NL0010832176
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization €33.42b
Enterprise Value €30.56b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.45
P/S ratio (TTM) P/S ratio 22.37
P/B ratio (TTM) P/B ratio 8.32
Revenue growth (TTM) Revenue growth 96.25%
Revenue (TTM) Revenue €1.49b
EBIT (operating result TTM) EBIT €-366.78m
Free Cash Flow (TTM) Free Cash Flow €-135.49m
EPS (TTM) EPS €-3.23
P/E forward 290.59
P/S forward 16.71
EV/Sales forward 15.28
Show more

Is arGEN-X a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

arGEN-X Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a arGEN-X forecast:

28x Buy
88%
4x Hold
13%

Analyst Opinions

32 Analysts have issued a arGEN-X forecast:

Buy
88%
Hold
13%

Financial data from arGEN-X

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1,494 1,494
96% 96%
100%
- Direct Costs 258 258
55% 55%
17%
1,236 1,236
108% 108%
83%
- Selling and Administrative Expenses 719 719
70% 70%
48%
- Research and Development Expense 780 780
28% 28%
52%
-263 -263
40% 40%
-18%
- Depreciation and Amortization 104 104
1% 1%
7%
EBIT (Operating Income) EBIT -367 -367
32% 32%
-25%
Net Profit -189 -189
51% 51%
-13%

In millions EUR.

Don't miss a Thing! We will send you all news about arGEN-X directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,148
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today